“Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis” (2025) SKIN The Journal of Cutaneous Medicine, 9(2), p. s553. doi:10.25251/skin.10.supp.553.